Clinical trial · Observational
A Study to Learn About the Effect of Avelumab First-Line Maintenance in Canadian People With Advanced Bladder Cancer
Treatment Effectiveness of Avelumab First-Line Maintenance Among Canadian Patients With Advanced Urothelial Carcinoma (TRAVELER)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): The trial was terminated for strategic reasons. The decision was not based on any safety and/or efficacy concerns.
Summary
Brief summary (as posted)
The purpose of this study is to learn about the safety and effects of the study medicine (called avelumab) for the treatment of advanced bladder cancer. This study is including participants who: * Participated in the Canadian avelumab patient support program * Have been diagnosed with advanced bladder cancer * Have been treated with platinum-based chemotherapy without their disease progressing All participants in this study have previously received avelumab first-line maintenance for the treatment of their advanced bladder cancer. Pfizer will examine the experiences of people receiving the study medicine. This will help determine the efficacy and safety of the study medicine for the treatment of bladder cancer.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bladder Cancer | Malignant Bladder Neoplasm | CURATED_EXACT | 0.92 |
| Bladder Tumors | Bladder Neoplasm | ALIAS | 0.90 |
| Urinary Bladder Neoplasms | Bladder Neoplasm | ALIAS | 0.90 |
| Urothelial Carcinoma | Urothelial Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Avelumab first-line maintenance | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Canadian Patients with Advanced Urothelial Carcinoma
- description
- Patients with LA/mUC who following 4-6 cycles of platinum chemotherapy and have not progressed, received avelumab, recommended dose of 10mg/kg body weight intravenously administered over 60 minutes every 2 weeks
- interventionNames
- Drug: Avelumab first-line maintenance
Primary outcomes (2)
- measure
- Overall survival
- timeFrame
- 12 months
- description
- OS from the date of avelumab initiation to the date of death from any cause
- measure
- Progression-free survival
- timeFrame
- 12 months
- description
- Progression-free survival from the date of avelumab first-line maintenance initiation to the date of progression or death from any cause
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Enrolled in the Canadian avelumab1LM Patient support program (PSP) * Histologically confirmed diagnosis of stage IV LA/mUC * No evidence of disease progression following first-line platinum-based chemotherapy * Receipt of avelumab1LM following 1L platinum-based chemotherapy * Received the last dose of chemotherapy no more than 10 weeks before entering the PSP * Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 * ≥6 months of follow-up from initiation of AVE 1LM therapy until study end date, unless the patient has died, with known date of death. Exclusion Criteria: * Diagnosed with LA/mUC and enrolled in the PSP, but did not receive avelumab * Pregnancy at index date * Participation in an interventional clinical trial at any point during the study period The index date will be considered as the initiation of index therapy. The index therapy will be considered as the avelumab 1LM treatment after 1L platinum-based chemotherapy.
References
Publications (0)
Data not yet available